Drug Type CRISPR/Cas9 |
Synonyms ADGN-123 |
Mechanism KRAS G12C inhibitors(GTPase KRas G12C inhibitors), KRAS G12D inhibitors(GTPase KRas G12D inhibitors), KRAS G12V inhibitors(GTPase KRas G12V inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 17 Apr 2023 | |
Neoplasms | Preclinical | FR | 17 Apr 2023 |